South Bend-based AgenDx Biosciences Inc. has closed on a more than $1.5 million seed round of financing. Investors include Elevate Ventures, South Bend-based The Judd Leighton Foundation Inc., the University of Notre Dame and IrishAngels Inc., a Chicago-based investment group focused on funding for startups connected to the Notre Dame community.

The early-stage company develops molecular diagnostics technology used in the treatment pancreatic cancer. Chief Executive Officer Kevin Connors says "we are delighted to have an excellent foundation of institutional and individual investors. We have made great progress toward the development of a platform that solves meaningful unmet clinical needs, and this capital will allow us to achieve additional critical engineering and clinical milestones."

AgenDx technology aims to identify biomarkers that tell doctors if commonly-used pancreatic cancer treatments are working. Ultimately, the company says the goal is to use its technology for early cancer detection.

AgenDx works with the Center for Microfluidics and Medical Diagnostics and the Harper Cancer Research Center at Notre Dame. You can connect to more about the company by clicking here.